Comparison of Asymmetric Dimethylarginine Levels Between Stages Three, Four, and Five Non-dialysis of Chronic Kidney Disease

Authors

  • Tri P Asmarawati Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Widodo Widodo Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • M Thaha Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Aditiawardana Aditiawardana Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Nunuk Mardiana Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Ardityo R Ardhany Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Artaria Tjempakasari Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Djoko Santoso Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Pranawa Pranawa Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Chandra Irwanadi Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

Keywords:

chronic kidney disease, asymmetric dimethylarginine (ADMA), cardiovascular disease

Abstract

Aim: to determine the differences of ADMA level between stages 3, 4, and 5 non-dialysis of chronic kidney disease (CKD) patients at Outpatient Nephrology Clinic, Dr. Soetomo Hospital. Methods: a cross-sectional study was conducted on stage 3, 4, and 5 non-dialysis CKD patients at Outpatient Nephrology Clinic, Dr. Soetomo Hospital, Surabaya from January to February 2015. Stages of CKD were determined based on GFR estimation according to 4-variable MDRD formula. Statistical analysis of differences in the levels of ADMA in three subject groups use one-way ANOVA test. Results:seventy-five patients were included in the study. Each group consisted of 25 patients stage 3, 4, and, 5 non-dialysis patients. Mean age of stage 3, stage 4, and stage 5 non-dialysis CKD patients were respectively 57.12 years, 54.80 years and 53.68 years. The mean levels of ADMA in stage 3, stage 4, and 5 were 0.62 (0.11) IU/mL, 0.72 (0.16) IU/mL, and 0.73 (0.18) IU/mL respectively. Analysis of the differences between the groups showed significant differences in ADMA levels (p=0.04), with the highest difference between stage 3 and stage 5. Conclusion:comparison of ADMA levels showed significant differences between CKD stages and the level tends to be higher along with increase severity of CKD stages.

Downloads

Published

2016-09-19

How to Cite

Asmarawati, T. P., Widodo, W., Thaha, M., Aditiawardana, A., Mardiana, N., Ardhany, A. R., Tjempakasari, A., Santoso, D., Pranawa, P., & Irwanadi, C. (2016). Comparison of Asymmetric Dimethylarginine Levels Between Stages Three, Four, and Five Non-dialysis of Chronic Kidney Disease. Acta Medica Indonesiana, 48(1), 28. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/134

Issue

Vol. 48 No. 1 (2016): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.